AMBS News and Press, Amarantus BioScience Holdings Inc From 12/09/19

NEW YORK, NY, Dec. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine a...

REHOVOT, Israel, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced ...

·          Patent extends patent coverage for eltoprazine to 2034 New York, NY - ( NewMediaWire ) - December 04, 2019 - Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechno...

·         Patent extends patent coverage for eltoprazine to 2034 New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JL...

Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa New York, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology...

Pending license with Emerald provides opportunity to realize therapeutic portfolio value JV w/Todos announces full enrollment for LymPro Alzheimer’s blood test clinical trial Amarantus management evaluating dividend of Todos shares to Amarantus shareholders after Todos Na...

Topline results expected before the end of Q1/2020 REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF) , a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurod...

NEW YORK , Oct. 25, 2019 /PRNewswire/ -- Emerald Organic Products, Inc. and Amarantus Bioscience Holdings today announced a principal agreement for the exclusive, worldwide license of several cutting-edge treatments, including Phase 3-ready therapies for ADHD and skin regeneration. ...

  Amarantus is receiving Emerald Preferred Stock with a minimum value of $100M in 2022   Treatment candidates are for Alzheimer’s, ADHD, Parkinson’s, severe burns and vision loss   Portfolio includes two Phase 3-ready programs NEW YORK, NY, Oct. 24,...

REHOVOT, Israel, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that Company management will prese...